Regeneron Teams With CytomX for Bispecific Cancer Therapies

Regeneron Pharmaceuticals and CytomX Therapeutics have partnered to develop bispecific cancer drugs in a deal whose value could exceed $2 billion.

Under the agreement, Regeneron will pay CytomX $30 million upfront and potential future milestone payments in addition to royalties on future global net sales.

The research is exploring the potential to create bispecifics that can remain inactive until activated by proteases — enzymes that speed up protein breakdown in tumors.

The approach could “widen the therapeutic window” and help reduce unwanted effects of T cell-engaging therapies, possibly even enabling them to treat tumor types that have previously been unresponsive to immunotherapy, the companies said.